A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.
Epistemonikos ID: b1471111e1f40fc615e4887aedc9cf0477e13eae
First added on: Aug 16, 2019